Small Cap Feast

30th April 2024

Dish of the day
No Joiners today
Off the menu
No leavers today

Dish Of The Day:



Wincanton (WIN.L) has left the Premium list of the Main Market
 Byotrol (BYOT.L) has left the AIM Market

Whats baking in the oven?

Potential Initial Public Offerings:

Reverse Takeovers:

16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radical Limited for a consideration of approximately £1.3m, payable by the issue of new ordinary shares in Electric Guitar. The Acquisition constitutes a reverse takeover under the Listing Rules and therefore shareholder approval for the Acquisition is being sought at a general meeting of Electric Guitar to be convened for 1 May 2024.

Change of Market:

TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM  market on 3 May 2024. Currently the market capitalisation of TheWorks is £16m.

Dual Listing :

Banquet Buffet

Avacta Group 47.5p £170m (AVCT.L)

The life sciences Company developing innovative, targeted cancer treatments and powerful diagnostics announces that Christina Coughlin, MD, PhD, has been appointed as the new Chief Executive Officer of Avacta, effective 1 May 2024. Dr Coughlin has served as a Board member since March 2022, was a consultant in clinical development and was Head of Research & Development since February 2024, driving the development of the preCISION platform from the bench to the bedside. After 19 years as CEO, Dr. Alastair Smith will be stepping down today.  

CloudCoCo Group 0.45p £3.2m (CLCO.L)

The provider of Managed IT services and communications solutions to private and public sector organisations announces its full year results for the year ended 30 September 2023. Revenue increased 7% to £26.0m (2022: £24.2m), Trading Group EBITDA increased 19% to £1.9m (2022: £1.6m), and cash and cash equivalents decreased to £794k (2022: £1.5m). While the current economic climate will continue to present near-term challenges, the work that has been completed to streamline and focus the Group and positions it well for continued progress in FY24, particularly in the areas of Cyber Security and Multi-cloud. 

KIBO Energy 0.0375p £1.7m (KIBO.L)

The renewable energy-focused development Company, announces the publication by its subsidiary, Mast Energy Developments, developer and operator in the rapidly growing flexible power market, of its audited financial results for the year end 31 December 2023. Revenue decreased to £341k (2022: £1.04m), the loss for the period increased to £3.54m (2022: £2.73m), and cash and cash equivalents decreased to £252 (2022: £132k). Post year-end, the Company secured alternative funding under a funding facility for up to £4m with RiverFort further to an agreement signed with MED subsidiary Pyebridge.

Kooth 278p £101.4m (KOO.L)

The youth digital mental well-being Company announces the appointment of Sherry Beth Husa to the Board as an independent non-executive Director with immediate effect. Sherry Beth Husa has more than 35 years' experience in building and improving the performance of managed care organisations in the USA. Sherry has extensive experience of leading and improving the operations, growth and profitability of significant US health insurance programmes.

Poolbeg Pharma* 11.75p £58.8m (POLB.L)

The biopharmaceutical Company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need announces its audited results for the year ended 31 December 2023. Cash and cash equivalents was £12.17m (2022: £16.19m) at the period end. During the period, the Company reported positive results from POLB001 LPS human challenge trial which revealed potent target inhibition and major reductions in key inflammatory markers. The period saw the strategic expansion of POLB001 as a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome. 2023 was an exceptional year for Poolbeg. The Company also separately announced that it had entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline for the treatment of oral ulcers in patient's suffering from Behçet's Disease. There is a clear unmet medical need for an effective treatment for this rare disease, which has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impact essential functions like eating, drinking and speaking. A Phase 2 trial has been successfully completed, demonstrating superiority over standard of care, it has Secured Orphan Drug Designation and Fast Track Designation from the FDA. With the growing focus on the rare and orphan disease space, Poolbeg is poised to capitalise on the significant opportunities presented by this attractive market.

Northcoders Group 150p £12m (CODE.L)

The technology training Group based in the UK announces its Final Results for the year ended 31 December 2023. Group revenue increased 27% to £7.1m (2022: £5.6m), adjusted EBITDA decreased to £0.1m (2022: £0.9m) and the Company had a cash balance of £1.6m (2022: £2.8m). Both B2C and B2B divisions started FY24 strongly, with record B2C applications and a growing pipeline for B2B contracts. Northcoders is trading in line with market expectations for FY24.

Smarttech247 22p £25.0m (S247.L)

The multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients today announces its unaudited interim results for the six months ending 31 January 2024. Revenues increased 17.4% to EUR 5.4m ( H1 2023: EUR 4.6m), adjusted EBITDA was EUR 125k (H1 23: EUR 1.15m); this is due to investments made to support future growth. The period ended with a cash balance of EUR 4.5m (H1 2023: EUR 6.0m). Cyber-attacks are on the increase with serious consequences for the companies involved. Smarttech247's combination of artificial intelligence-led managed detection and response capabilities can help to significantly reduce the impact and help manage the situation.   

Strip Tinning Holdings 46p £8.4m (STG.L)

The supplier of specialist connection systems to the automotive sector announces its full year results for the year ended 31 December 2023. Revenue increased to £10.8m (2022: £10.2m), adjusted EBITDA increased to £0.1m (2022: loss £2.2m) and there was a cash balance of £0.3m (2022: £1.3m). Strong momentum has already been demonstrated in 2024 with two significant new wins announced in the emerging "smart" glass market, in which Strip Tinning benefits from first mover advantage, with sales growth coming in 2025 once serial production commences.

Transense Technologies 101.5p £15.4m (TRT.L)

The Company announces that it has formally joined an Aerospace Technology Institute supported project, LANDOne, with Airbus to provide SAWsense technology and support the development of next generation landing-systems technology. LANDOne is a £37.8m project looking into new lighter, lower maintenance landing gear systems. Officially launched in 2022, Transense has joined the project due to the SAWsense technology potentially allowing critical measurements to be made that were not possible with other technologies.

Vox Valor Capital* 0.2p £4.7m (VOX.L)

The marketing technology, digital content, mobile games/apps and digital marketing Company announces its audited final results for the financial year ended 31 December 2023. Revenue decreased to $5.6m (2022: $13.8m), due to the disposal of the Russian subsidiary. There was an operating loss of $90k (2022: Profit $29k), total comprehensive income of $469k (2022: loss $5.5m) due to forex gains of $653k and cash balance of $144k (2022: $911k). The Company is continuing to identify potential acquisitions that are complimentary to the Group’s strategy where it can generate meaningful synergies from its mobile marketing expertise and technology. The organic growth plans of the Group include the expansion of the Group’s mobile marketing services and technology offer (Mobio) in the UK, Europe and the United States.


30 April 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram